Facchinetti F.; Mazzaschi G.; Barbieri F.; Passiglia F.; Mazzoni F.; Berardi R.; Proto C.; Cecere F.L.; Pilotto S.; Scotti V.; Rossi S.; Del Conte A.; Vita E.; Bennati C.; Ardizzoni A.; Cerea G.; Migliorino M.R.; Sala E.; Camerini A.; Bearz A.; De Carlo E.; Zanelli F.; Guaitoli G.; Garassino M.C.; Ciccone L.P.; Sartori G.; Toschi L.; Dall'Olio F.G.; Landi L.; Pizzutilo E.G.; Bartoli G.; Baldessari C.; Novello S.; Bria E.; Cortinovis D.L.; Rossi G.; Rossi A.; Banna G.L.; Camisa R.; Di Maio M.; Tiseo M., First-line pembrolizumab in advanced non–small cell lung cancer patients with poor performance status, «EUROPEAN JOURNAL OF CANCER», 2020, 130, pp. 155 - 167 [articolo]
Di Nunno, Vincenzo; Mollica, Veronica; Schiavina, Riccardo; Nobili, Elisabetta; Fiorentino, Michelangelo; Brunocilla, Eugenio; Ardizzoni, Andrea; Massari, Francesco, Improving IMDC Prognostic Prediction Through Evaluation of Initial Site of Metastasis in Patients With Metastatic Renal Cell Carcinoma, «CLINICAL GENITOURINARY CANCER», 2020, 18, pp. e83 - e90 [articolo]
Di Nunno, Vincenzo; Mollica, Veronica; Schiavina, Riccardo; Nobili, Elisabetta; Fiorentino, Michelangelo; Brunocilla, Eugenio; Ardizzoni, Andrea; Massari, Francesco, Improving IMDC Prognostic Prediction Through Evaluation of Initial Site of Metastasis in Patients With Metastatic Renal Cell Carcinoma, «CLINICAL GENITOURINARY CANCER», 2020, 18, pp. 83 - 90 [articolo]
Raschi E.; Gatti M.; Gelsomino F.; Ardizzoni A.; Poluzzi E.; De Ponti F., Lessons to be Learnt from Real-World Studies on Immune-Related Adverse Events with Checkpoint Inhibitors: A Clinical Perspective from Pharmacovigilance, «TARGETED ONCOLOGY», 2020, 15, pp. 449 - 466 [articolo]Open Access
Lamberti G.; Gelsomino F.; Brocchi S.; Poerio A.; Melotti B.; Sperandi F.; Gargiulo M.; Borghi C.; Fiorentino M.; Ardizzoni A., New disappearance of complicated atheromatous plaques on rechallenge with PD-1/PD-L1 axis blockade in non-small cell lung cancer patient: follow up of an unexpected event, «THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY», 2020, 12, pp. 1 - 6 [articolo]Open Access
Massari F.; Mollica V.; Salvagni S.; Tognetto M.; Ardizzoni A., Oncology clinical trials in the time of COVID-19: How a pandemic can revolutionize patients' care, «FUTURE ONCOLOGY», 2020, 16, pp. 1413 - 1415 [articolo]Open Access
Gelsomino F.; Di Federico A.; Filippini D.M.; Dall'Olio F.G.; Lamberti G.; Sperandi F.; Balacchi C.; Brocchi S.; Ardizzoni A., Overcoming Primary Resistance to PD-1 Inhibitor With Anti–PD-L1 Agent in Squamous-Cell NSCLC: Case Report, «CLINICAL LUNG CANCER», 2020, 21, pp. E45 - E48 [articolo]
Cavazzoni A.; Digiacomo G.; Alfieri R.; La Monica S.; Fumarola C.; Galetti M.; Bonelli M.; Cretella D.; Barili V.; Zecca A.; Giovannetti E.; Fiorentino M.; Tiseo M.; Petronini P.G.; Ardizzoni A., Pemetrexed enhances membrane PD-L1 expression and potentiates T cell-mediated cytotoxicity by anti-PD-L1 antibody therapy in non-small-cell lung cancer, «CANCERS», 2020, 12, Article number: 666, pp. 1 - 16 [articolo]Open Access
Sartore-Bianchi A.; Lonardi S.; Martino C.; Fenocchio E.; Tosi F.; Ghezzi S.; Leone F.; Bergamo F.; Zagonel V.; Ciardiello F.; Ardizzoni A.; Amatu A.; Bencardino K.; Valtorta E.; Grassi E.; Torri V.; Bonoldi E.; Sapino A.; Vanzulli A.; Regge D.; Cappello G.; Bardelli A.; Trusolino L.; Marsoni S.; Siena S., Pertuzumab and trastuzumab emtansine in patients with HER2-amplified metastatic colorectal cancer: The phase II HERACLES-B trial, «ESMO OPEN», 2020, 5, Article number: e000911, pp. 1 - 8 [articolo]Open Access
Gelsomino F.; Tiseo M.; Barbieri F.; Riccardi F.; Cavanna L.; Frassoldati A.; Delmonte A.; Longo L.; Dazzi C.; Cinieri S.; Colantonio I.; Sperandi F.; Lamberti G.; Brocchi S.; Tofani L.; Boni L.; Ardizzoni A., Phase 2 study of NAB-paclitaxel in SensiTivE and refractory relapsed small cell lung cancer (SCLC) (NABSTER TRIAL), «BRITISH JOURNAL OF CANCER», 2020, 123, pp. 26 - 32 [articolo]Open Access
Trisolini R.; Cancellieri A.; Livi V.; Annema J.T.; Ferrari M.; Natali F.; Paioli D.; Conci N.; Altimari A.; Fiorentino M.; Ardizzoni A., Pulmonary adenocarcinoma with psammoma bodies is associated with a specific endobronchial ultrasound pattern and a high prevalence of actionable driver mutations, «LUNG CANCER», 2020, 147, pp. 204 - 208 [articolo]
Ponce Aix S.; Talbot D.; Govindan R.; Dols M.C.; Postmus P.E.; Lewanski C.; Bennouna J.; Fischer J.R.; Juan-Vidal O.; Stewart D.J.; Ardizzoni A.; Bhore R.; Wolfsteiner M.; Reck M.; Ong T.J.; Morgensztern D., Quality of life with second or third line nab-paclitaxel-based regimens in advanced non-small-cell lung cancer, «FUTURE ONCOLOGY», 2020, 16, pp. 749 - 762 [articolo]
Cuicchi D.; Di Fabio F.; Guido A.; Llimpe F.L.R.; Morganti A.G.; Ardizzoni A.; Coscia M.; Poggioli G., Randomized Pilot Trial of Percutaneous Posterior Tibial Nerve Stimulation Versus Medical Therapy for the Treatment of Low Anterior Resection Syndrome: One-Year Follow-up, «DISEASES OF THE COLON & RECTUM», 2020, 63, pp. 1602 - 1609 [articolo]
Ricci C.; Capizzi E.; Giunchi F.; Casolari L.; Gelsomino F.; Rihawi K.; Natali F.; Livi V.; Trisolini R.; Fiorentino M.; Ardizzoni A., Reliability of programmed death ligand 1 (PD-L1) tumor proportion score (TPS) on cytological smears in advanced non-small cell lung cancer: a prospective validation study, «THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY», 2020, 12, Article number: 1758835920954802, pp. 1 - 8 [articolo]Open Access
Di Nunno V.; Santoni M.; Mollica V.; Conti A.; Montironi R.; Battelli N.; Ardizzoni A.; Massari F., Systemic Treatment for Metastatic Hormone Sensitive Prostate Cancer: A Comprehensive Meta-Analysis Evaluating Efficacy and Safety in Specific Sub-Groups of Patients, «CLINICAL DRUG INVESTIGATION», 2020, 40, pp. 211 - 226 [articolo]
